Impact of Surgical Margins in Breast Cancer After Preoperative Systemic Chemotherapy on Local Recurrence and SurvivalKerstin Wimmer, Florian Fitzal, Michael Bolliger et al.|Annals of Surgical Oncology|2019Cited by 44
Emergence of immune-related adverse events correlates with pathological complete response in patients receiving pembrolizumab for early triple-negative breast cancerMaximilian Marhold, Rupert Bartsch, A. Halstead et al.|OncoImmunology|2023Cited by 30
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patientsKerstin Wimmer, Florian Fitzal, Monika Sachet et al.|Journal of Experimental & Clinical Cancer Research|2023Cited by 18
Abstract P3-06-10: Immune-related adverse events (irAEs) and pathological complete response (pCR) rates in patients receiving neoadjuvant chemotherapy (CHT) and pembrolizumab (PEM) for early triple-negative breast cancer (eTNBC)Maximilian Marhold, Rupert Bartsch, Simon Udovica et al.|Cancer Research|2023Cited by 2
Supplemental Material for: Retrospective analysis of real-world elacestrant use in two large Austrian cancer centersfigshare admin karger, Maximilian Marhold, Lisa Vesenmayer et al.|Figshare|2026Cited by 0